Top Markets
#1 Akedo Akedo +56.93%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.96%
#4 Velvet Velvet +38.88%
#5 Black Phoenix Black Phoenix +34.53%
#6 Ο„emplar Ο„emplar +24.12%
#7 Ribbita by Virtuals Ribbita by Virtuals +17.94%
#8 Cap Cap +16.45%
#9 Bitway Bitway +16.28%
#10 Cross Cross +15.22%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Avalon GloboCare Corp. Avalon GloboCare Corp.

Avalon GloboCare Corp.

ALBT
Rank in Stocks #38549
Avalon GloboCare Corp., along with its affiliated entities, manages and holds... Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AVA-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.
Share Price
$0.2184
Last synced: 2026-07-28
Market Cap
$923.17K
Change (1 day)
-4.25%
Change (1 year)
-90.03%
Country
US
Trade Avalon GloboCare Corp. (ALBT)

Category

Healthcare
Number of shares outstanding for Avalon GloboCare Corp. (ALBT)
Number of shares outstanding as of August 2026: 0
According to Avalon GloboCare Corp. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Avalon GloboCare Corp. (ALBT) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -
BE